Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $310
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $300 to $310.
October 25, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst has maintained an Outperform rating on Amgen and raised the price target from $300 to $310.
The news is directly about Amgen and is positive. The Outperform rating indicates that the analyst expects the stock to do better than the market average. The increase in price target from $300 to $310 suggests that the analyst believes the stock has potential for further growth. This could lead to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100